General
Preferred name
tirofiban
Synonyms
Tirofiban HCl ()
MK-383 ()
L700462 ()
Aggrastat ()
MK383 ()
MK-383 Hydrochloride monohydrate ()
Tirofiban hydrochloride monohydrate ()
TIROFIBAN HYDROCHLORIDE ()
Tirofiban HCl Hydrate ()
Tirofiban (hydrochloride monohydrate) ()
L700462 (hydrochloride monohydrate) ()
MK383 (hydrochloride monohydrate) ()
MK-383 Hydrochloride ()
Tirofiban (hydrochloride hydrate) ()
Tirofiban hydrochloride anhydrous ()
L-700,462 ()
L-700462 ()
Agrastat ()
P&D ID
PD009726
CAS
150915-40-5
144494-65-5
142373-60-2
1331911-68-2
Tags
available
drug
Approved by
FDA
First approval
1998
Drug indication
Acute coronary syndrome
Myocardial infarction
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area[1][2][3].
PRICE
63
DESCRIPTION
Tirofiban is a rapidly-active but short-acting glycoprotein IIb/IIIa inhibitor type antiplatelet drug.
(GtoPdb)
PRICE
58
DESCRIPTION
Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Tirofiban (MK-383, Aggrastat) is a nonpeptide derivative of tyrosine that selectively inhibits the GP-IIb/IIIa receptor, with minimal effects on the ɑvβ3 vitronectin receptor.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Tirofiban (L700462) (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
28
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
80
Molecular Weight
440.23
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
14
Ring Count
2
Aromatic Ring Count
1
cLogP
2.95
TPSA
104.73
Fraction CSP3
0.68
Chiral centers
1.0
Largest ring
6.0
QED
0.38
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
GPIIb/IIIa
Integrin
ADP
ITGA2B, ITGB3
Member status
member
MOA
Integrin binder
Integrin alpha-2/beta-3 antagonist
platelet aggregation inhibitor, structural glycoprotein antagonist
Indication
myocardial infarction, refactory angina
Therapeutic Class
Fibrinolytic Agents
Pathway
cytoskeleton
Cytoskeletal Signaling
Membrane Transporter/Ion Channel
Source data
